11.06.2013 - Bill Gates and EU Research Commissioner Máire Geoghegan-Quinn have signed a partnership to fight neglected diseases.
The multibillion partnership of the Bill & Melinda Gates Foundation and the European Commission aims at fighting and other poverty-related diseases such as HIV/AIDS, tuberculosis malaria, lymphatic filariasis or sleeping sickness, which affect more than one billion people globally. "The foundation is completely committed to supporting efforts to develop life-saving products to help solve some of the world’s toughest problems“, said Gates. The partnership will develop at least one improved product per year, according to Geoghegan-Quinn.
Much of the work will be carried out through the European and Developing Countries Clinical Trials Partnership (EDCTP), which so far involves 16 European and 30 sub-Saharan African countries. The European Commission has proposed funding of up to €1 bn from the EU budget to match the contributions of the European partner countries.
Between 2007 and 2011, Gates and the EU invested around €2.4bn in R&D on neglected infectious diseases. Under the agreement, the partners will develop new drugs, vaccines and diagnostics suited to the needs of the population of poor countries , improve health systems and ensure the delivery of such products. Furthermore, the Gates Foundation and the Commission will launch a joint innovation prize in 2014 in order to honour current approaches to global health.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.